Comparison of the therapeutic efficacy of benzalkonium bromide, pirarubicin, and mitomycin C in prevention of postoperative recurrence of superficial bladder cancer
10.3781/j.issn.1000-7431.2008.12.009
- Author:
Ming-Gen YANG
1
Author Information
1. Department of Urology
- Publication Type:Journal Article
- Keywords:
Bladder neoplasms;
Chemotherapy, cancer, regional perfusion;
Neoplasm recurrence
- From:
Tumor
2008;28(12):1055-1058
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the effectiveness and safety of bladder instillation of bzalkonium bromide (BR), pirarubicin (THP), or mitomycin C (MMC) in prevention of postoperative recurrence of superficial bladder transient cell carcinoma (SBTCC). Methods: One hundred and twenty-seven patients with SBTCC who underwent transurethral resection of bladder tumor (TURBt) or partial cystectomy were randomly divided into 3 groups. BA group (n = 43) received intravesical instillation of 0.1% BB 300 mL and retained for 15 min for one time. THP group (n = 42) received intravesical instillation of 30 mg THP in 50 mL of 0.9% NaCl solution. MMC group (n = 42) received intravesical instillation of 40 mg MMC in 50 mL of 0.9% NaCl solution. THP and MMC were given to patients once a week for 8 weeks and then once a month for one year. All the patients were followed up and received cystoscopy examination. The recurrence rate and side effects were compared between the three groups. Results: All patients were followed up for 24 months. The tumor recurrent rates were 4.7%, 23.8%, and 26.2% in BB, THP, and MMC groups, respectively. The tumor recurrence rate of BB group was significantly lower than that in THP and MMC groups (P <0.005). The difference was not significant between THP and MMC group (P >0.05). The pathological grade, clinical staging, primary and recurrent tumors, and different instillation drug therapies had significant effects on the recurence rate (P <0.05). There was no statistical significance in the incidence rate of renal damage among the three groups (P >0.05). Conclusion: Postoperative intravesical administration of BB is more effective than THP and MMC with well toleration and low cost. No apparent side effects are observed.
